Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spleenless patients under the microscope: can we predict their biggest health threats?

NCT ID NCT04199403

Knowledge-focused Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study follows 6,000 adults in France who have had their spleen removed or rendered non-functional due to surgery, radiation, or embolization. Researchers aim to identify risk factors for serious complications such as infections, cancer, and blood clots. By comparing different causes of asplenia, the study hopes to improve long-term monitoring and care for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better monitoring guidelines and earlier detection of complications in people without a functioning spleen.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to all types of asplenia or to non-French populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Jan 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients \>18 years with acquired asplenia due to splenectomy, artery embolization, or spleen radiotherapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 year-old * With asplenia due to splenectomy, splenic artery embolization or radiotherapy Exclusion Criteria: * Genetic asplenia including sick cell disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asplenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial isolated congenital asplenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asplenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • C.H. Victor Dupouy

    RECRUITING

    Argenteuil, 95100, France

  • C.H. d'Angoulême

    RECRUITING

    Angoulême, 16959, France

  • C.H. de Béthune

    WITHDRAWN

    Béthune, 62660, France

  • C.H. de Tourcoing

    RECRUITING

    Tourcoing, 59208, France

  • C.H. de Valenciennes

    RECRUITING

    Valenciennes, 59300, France

  • C.H.U. de Lille

    RECRUITING

    Lille, 59037, France

  • C.H.U. de Montpellier

    RECRUITING

    Montpellier, 34295, France

  • C.H.U. de Poitiers

    RECRUITING

    Poitiers, 86000, France

  • C.H.U. de Rouen

    NOT_YET_RECRUITING

    Rouen, 76031, France

  • C.H.U. de Toulouse

    RECRUITING

    Toulouse, 31059, France

  • Hôpitaux de Chartres

    ACTIVE_NOT_RECRUITING

    Chartres, 28019, France

  • Hôtel-Dieu - CHU de Nantes

    RECRUITING

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.